{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:51:48Z","timestamp":1792266708172,"version":"4.4.0"},"reference-count":67,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,10,26]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although CAR T-cell therapy is US Food and Drug Administration\u2013approved for B-cell non-Hodgkin lymphomas, the development of adoptive immunotherapy for the treatment of classic Hodgkin lymphoma (cHL) has not accelerated at a similar pace. Adoptive T-cell therapy with Epstein-Barr virus\u2013specific cytotoxic T lymphocytes and CD30 CAR T cells have demonstrated significant clinical responses in early clinical trials of patients with cHL. Additionally, CD19 and CD123 CAR T cells that target the immunosuppressive tumor microenvironment in cHL have also been investigated. Here we discuss the landscape of clinical trials of adoptive immunotherapy for patients with cHL with a view toward current challenges and novel strategies to improve the development of CAR T-cell therapy for cHL.<\/jats:p>","DOI":"10.1182\/bloodadvances.2021005304","type":"journal-article","created":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T01:51:14Z","timestamp":1633485074000},"page":"4291-4302","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":19,"title":["Adoptive T-cell therapy for Hodgkin lymphoma"],"prefix":"10.1182","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4437-9377","authenticated-orcid":false,"given":"Carrie","family":"Ho","sequence":"first","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ruella","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and"},{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6971-8465","authenticated-orcid":false,"given":"Bruce L.","family":"Levine","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and"},{"name":"Center for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Svoboda","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2021,10,26]]},"reference":[{"issue":"21","key":"2021102615243617200_B1","doi-asserted-by":"crossref","first-page":"4634","DOI":"10.1200\/JCO.2005.09.085","article-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin\u2019s lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","volume":"23","author":"Meyer","year":"2005","journal-title":"J Clin Oncol."},{"issue":"7","key":"2021102615243617200_B2","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa1000067","article-title":"Reduced treatment intensity in patients with early-stage Hodgkin\u2019s lymphoma","volume":"363","author":"Engert","year":"2010","journal-title":"N Engl J Med."},{"issue":"6","key":"2021102615243617200_B3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1200\/JCO.2012.43.4803","article-title":"Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)","volume":"31","author":"Gordon","year":"2013","journal-title":"J Clin Oncol."},{"issue":"5","key":"2021102615243617200_B4","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/j.1365-2141.2003.04828.x","article-title":"Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin\u2019s disease","volume":"124","author":"Moskowitz","year":"2004","journal-title":"Br J Haematol."},{"issue":"19","key":"2021102615243617200_B5","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med."},{"issue":"4","key":"2021102615243617200_B6","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med."},{"issue":"1","key":"2021102615243617200_B7","doi-asserted-by":"crossref","first-page":"e0004","DOI":"10.5041\/RMMJ.10179","article-title":"Adoptive T cell immunotherapy for cancer","volume":"6","author":"Perica","year":"2015","journal-title":"Rambam Maimonides Med J."},{"issue":"1","key":"2021102615243617200_B8","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med."},{"issue":"6382","key":"2021102615243617200_B9","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science."},{"issue":"4","key":"2021102615243617200_B10","doi-asserted-by":"crossref","first-page":"e1295202","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?","volume":"6","author":"Nijland","year":"2017","journal-title":"OncoImmunology."},{"issue":"9","key":"2021102615243617200_B11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer."},{"issue":"177","key":"2021102615243617200_B12","doi-asserted-by":"crossref","first-page":"177ra38","DOI":"10.1126\/scitranslmed.3005930","article-title":"CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia","volume":"5","author":"Brentjens","year":"2013","journal-title":"Sci Transl Med."},{"issue":"26","key":"2021102615243617200_B13","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med."},{"issue":"10","key":"2021102615243617200_B14","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1172\/JCI61245","article-title":"Hodgkin lymphoma","volume":"122","author":"K\u00fcppers","year":"2012","journal-title":"J Clin Invest."},{"issue":"21","key":"2021102615243617200_B15","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin\u2019s lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J Clin Oncol."},{"issue":"23","key":"2021102615243617200_B16","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and pd-l2 genetic alterations define classical Hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol."},{"issue":"14","key":"2021102615243617200_B17","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin\u2019s lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J Clin Oncol."},{"issue":"12","key":"2021102615243617200_B18","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1182\/blood-2002-01-0099","article-title":"The role of cytokines in classical Hodgkin lymphoma","volume":"99","author":"Skinnider","year":"2002","journal-title":"Blood."},{"issue":"5","key":"2021102615243617200_B19","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood-2003-07-2594","article-title":"Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma","volume":"103","author":"Marshall","year":"2004","journal-title":"Blood."},{"issue":"12","key":"2021102615243617200_B20","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood-2004-08-3337","article-title":"Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis","volume":"105","author":"Dotti","year":"2005","journal-title":"Blood."},{"issue":"12","key":"2021102615243617200_B21","doi-asserted-by":"crossref","first-page":"e114345","DOI":"10.1371\/journal.pone.0114345","article-title":"Macrophages and dendritic cells as actors in the immune reaction of classical Hodgkin lymphoma","volume":"9","author":"Tudor","year":"2014","journal-title":"PLoS One."},{"issue":"10","key":"2021102615243617200_B22","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin\u2019s lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med."},{"issue":"1","key":"2021102615243617200_B23","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12916-016-0711-6","article-title":"Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma","volume":"14","author":"Guo","year":"2016","journal-title":"BMC Med."},{"issue":"17","key":"2021102615243617200_B24","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood."},{"issue":"6","key":"2021102615243617200_B25","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res."},{"issue":"6","key":"2021102615243617200_B26","doi-asserted-by":"crossref","first-page":"3220","DOI":"10.1182\/blood-2007-05-085159","article-title":"PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma","volume":"111","author":"Yamamoto","year":"2008","journal-title":"Blood."},{"issue":"22","key":"2021102615243617200_B27","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood."},{"issue":"23","key":"2021102615243617200_B28","first-page":"2059","article-title":"The microenvironmental niche in classic Hodgkin lymphoma is enriched for CTLA-4-positive T cells that are PD-1-negative","volume":"134","author":"Patel","year":"2019","journal-title":"Blood."},{"issue":"7","key":"2021102615243617200_B29","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1182\/blood-2008-07-168468","article-title":"CTLA4 blockade with ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation","volume":"113","author":"Bashey","year":"2009","journal-title":"Blood."},{"issue":"3","key":"2021102615243617200_B30","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1158\/2159-8290.CD-19-0680","article-title":"Single-cell transcriptome analysis reveals disease-defining T-cell subsets in the tumor microenvironment of classic Hodgkin lymphoma","volume":"10","author":"Aoki","year":"2020","journal-title":"Cancer Discov."},{"issue":"3","key":"2021102615243617200_B31","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.blre.2003.12.002","article-title":"Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease","volume":"18","author":"Burns","year":"2004","journal-title":"Blood Rev."},{"issue":"11","key":"2021102615243617200_B32","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood-2011-08-371971","article-title":"Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation","volume":"119","author":"Doubrovina","year":"2012","journal-title":"Blood."},{"issue":"5","key":"2021102615243617200_B33","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood-2009-08-239186","article-title":"Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients","volume":"115","author":"Heslop","year":"2010","journal-title":"Blood."},{"issue":"4","key":"2021102615243617200_B34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/(SICI)1097-0215(19970207)70:4<375::AID-IJC1>3.0.CO;2-T","article-title":"Epstein-Barr virus-associated Hodgkin\u2019s disease: epidemiologic characteristics in international data","volume":"70","author":"Glaser","year":"1997","journal-title":"Int J Cancer."},{"issue":"7","key":"2021102615243617200_B35","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1182\/blood.V87.7.2918.bloodjournal8772918","article-title":"Frequent expression of interleukin-10 by Epstein-Barr virus-harboring tumor cells of Hodgkin\u2019s disease","volume":"87","author":"Herbst","year":"1996","journal-title":"Blood."},{"issue":"8","key":"2021102615243617200_B36","doi-asserted-by":"crossref","first-page":"2925","DOI":"10.1182\/blood.V91.8.2925.2925_2925_2934","article-title":"Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the treatment of patients with EBV-positive relapsed Hodgkin\u2019s disease","volume":"91","author":"Roskrow","year":"1998","journal-title":"Blood."},{"issue":"4","key":"2021102615243617200_B37","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/00002371-200407000-00008","article-title":"The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease","volume":"27","author":"Bollard","year":"2004","journal-title":"J Immunother."},{"issue":"12","key":"2021102615243617200_B38","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1084\/jem.20040890","article-title":"Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin\u2019s disease","volume":"200","author":"Bollard","year":"2004","journal-title":"J Exp Med."},{"issue":"8","key":"2021102615243617200_B39","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1200\/JCO.2013.51.5304","article-title":"Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins","volume":"32","author":"Bollard","year":"2014","journal-title":"J Clin Oncol."},{"issue":"11","key":"2021102615243617200_B40","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1200\/JCO.2017.74.3179","article-title":"Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed Hodgkin lymphoma","volume":"36","author":"Bollard","year":"2018","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021102615243617200_B41","doi-asserted-by":"crossref","first-page":"194","DOI":"10.3390\/cancers10060194","article-title":"TGF-\u03b2 in T cell biology: implications for cancer immunotherapy","volume":"10","author":"Dahmani","year":"2018","journal-title":"Cancers (Basel)."},{"issue":"7","key":"2021102615243617200_B42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther."},{"issue":"5","key":"2021102615243617200_B43","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1097\/CJI.0b013e318177092b","article-title":"Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-\u03b2 receptor","volume":"31","author":"Foster","year":"2008","journal-title":"J Immunother."},{"issue":"22","key":"2021102615243617200_B44","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1182\/blood-2018-07-863654","article-title":"EBV\/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation","volume":"132","author":"McLaughlin","year":"2018","journal-title":"Blood."},{"issue":"9","key":"2021102615243617200_B45","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/cncr.20188","article-title":"Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease","volume":"100","author":"Lucas","year":"2004","journal-title":"Cancer."},{"issue":"2","key":"2021102615243617200_B46","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jcyt.2018.08.001","article-title":"Epstein-Barr Virus (EBV)-derived BARF1 encodes CD4- and CD8-restricted epitopes as targets for T-cell immunotherapy","volume":"21","author":"Kalra","year":"2019","journal-title":"Cytotherapy"},{"issue":"6","key":"2021102615243617200_B47","doi-asserted-by":"crossref","first-page":"468","DOI":"10.7555\/JBR.28.20140066","article-title":"T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo","volume":"28","author":"Tang","year":"2014","journal-title":"J Biomed Res."},{"issue":"9","key":"2021102615243617200_B48","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1038\/bcj.2017.85","article-title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","volume":"7","author":"van der Weyden","year":"2017","journal-title":"Blood Cancer J."},{"issue":"12","key":"2021102615243617200_B49","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood."},{"issue":"9980","key":"2021102615243617200_B50","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet."},{"issue":"4","key":"2021102615243617200_B51","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med."},{"issue":"5","key":"2021102615243617200_B52","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/1078-0432.CCR-16-1365","article-title":"Autologous T cells expressing CD30 chimeric antigen receptors for relapsed or refractory Hodgkin lymphoma: an open-label phase I trial","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"9","key":"2021102615243617200_B53","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1172\/JCI94306","article-title":"Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes","volume":"127","author":"Ramos","year":"2017","journal-title":"J Clin Invest."},{"issue":"32","key":"2021102615243617200_B54","doi-asserted-by":"crossref","first-page":"3794","DOI":"10.1200\/JCO.20.01342","article-title":"Anti-CD30 CAR-T cell therapy in relapsed and refractory Hodgkin lymphoma","volume":"38","author":"Ramos","year":"2020","journal-title":"J Clin Oncol."},{"issue":"6","key":"2021102615243617200_B55","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0002-9440(10)65424-7","article-title":"High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin\u2019s lymphoma","volume":"154","author":"van den Berg","year":"1999","journal-title":"Am J Pathol."},{"issue":"11","key":"2021102615243617200_B56","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","article-title":"Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege","volume":"66","author":"Ishida","year":"2006","journal-title":"Cancer Res."},{"issue":"25","key":"2021102615243617200_B57","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood."},{"issue":"10","key":"2021102615243617200_B58","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood-2018-03-837609","article-title":"Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma","volume":"132","author":"Svoboda","year":"2018","journal-title":"Blood."},{"issue":"23","key":"2021102615243617200_B59","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1182\/blood-2008-11-189688","article-title":"Circulating clonotypic B cells in classic Hodgkin lymphoma","volume":"113","author":"Jones","year":"2009","journal-title":"Blood."},{"issue":"2","key":"2021102615243617200_B60","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/cyto.b.20561","article-title":"Flow cytometric analysis of CD123 is useful for immunophenotyping classical Hodgkin lymphoma","volume":"80","author":"Fromm","year":"2011","journal-title":"Cytometry B Clin Cytom."},{"issue":"3","key":"2021102615243617200_B61","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/10428190400013712","article-title":"The role of interleukin-3 in classical Hodgkin\u2019s disease","volume":"46","author":"Aldinucci","year":"2005","journal-title":"Leuk Lymphoma."},{"issue":"10","key":"2021102615243617200_B62","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1158\/2159-8290.CD-16-0850","article-title":"Overcoming the immunosuppressive tumor microenvironment of Hodgkin lymphoma using chimeric antigen receptor T cells","volume":"7","author":"Ruella","year":"2017","journal-title":"Cancer Discov."},{"issue":"3","key":"2021102615243617200_B63","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol."},{"issue":"10","key":"2021102615243617200_B64","doi-asserted-by":"crossref","first-page":"e26286","DOI":"10.4161\/onci.26286","article-title":"Blockade of PD-1 immunosuppression boosts CAR T-cell therapy","volume":"2","author":"John","year":"2013","journal-title":"OncoImmunology."},{"issue":"22","key":"2021102615243617200_B65","doi-asserted-by":"crossref","first-page":"6982","DOI":"10.1158\/1078-0432.CCR-17-0867","article-title":"Enhanced cancer immunotherapy by chimeric antigen receptor-modified T cells engineered to secrete checkpoint inhibitors","volume":"23","author":"Li","year":"2017","journal-title":"Clin Cancer Res."},{"key":"2021102615243617200_B66","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 enhanced the anti-tumor activity of chimeric antigen receptor T cells against hepatocellular carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front Pharmacol."},{"issue":"6481","key":"2021102615243617200_B67","doi-asserted-by":"crossref","first-page":"eaba7365","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4291\/1830445\/advancesadv2021005304.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/5\/20\/4291\/1830445\/advancesadv2021005304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T03:27:43Z","timestamp":1699586863000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/5\/20\/4291\/477174\/Adoptive-T-cell-therapy-for-Hodgkin-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,26]]},"references-count":67,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2021,10,26]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2021005304","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,26]]}}}